Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489387 | 0.90 | MAPT (0.60) | GAAMAPTMEN1KMT2AALOX12 | |
| SCHEMBL28407357 | 0.66 | SNCA (0.47) | GAAMAPTMEN1KMT2AALOX12 | |
| SCHEMBL4003937 | 0.65 | CA12 (0.70) | MAPTMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL2313707 | 0.65 | CA12 (0.70) | MAPTMEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL31083917 | 0.65 | CA12 (0.70) | MAPTMEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL14321044 | 0.65 | ALDH1A1 (0.54) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL234030 | 0.65 | TSHR (0.60) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL17022287 | 0.64 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5273471 | 0.64 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL289045 | 0.64 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2311831-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | Abbott Laboratories (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-1620434-B1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1620434-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | GAA 1962/4885MAPT 3194/4885MEN1 1093/4885 |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | GAA 1593/4885MAPT 2699/4885MEN1 1649/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | GAA 1225/4885MAPT 983/4885MEN1 2046/4885 |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | GAA 1593/4885MAPT 2699/4885MEN1 1649/4885 |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | HRH3, HRH4, HRH2 | GAA 1593/4885MAPT 2699/4885MEN1 1649/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | GAA 1962/4885MAPT 3194/4885MEN1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.